Total trials
662
Active
138
Phase 3
34
Total enrollment
285,007
Pipeline matrix
Showing 40 of 93 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Insulin | — | — | — | — | 3 | ||
| Bupivacaine | — | — | — | — | 2 | ||
| Liraglutide | — | — | — | — | — | 2 | |
| Dupilumab Injectable Product | — | — | — | — | — | 1 | |
| Metformin + Insulin | — | — | — | — | — | 1 | |
| Aspirin 81Mg Ec Tab | — | — | — | — | — | 1 | |
| Aspirin 162Mg Ec Tab | — | — | — | — | — | 1 | |
| Colchicine 0.6 mg | — | — | — | — | — | 1 | |
| Control/Placebo group | — | — | — | — | — | 1 | |
| Dupilumab Prefilled Syringe | — | — | — | — | — | 1 | |
| Liraglutide + Exercise training | — | — | — | — | — | 1 | |
| GLP-1RA | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | 4 | |||
| Levetiracetam | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| T-DM1 | — | — | — | — | — | 1 | |
| Hydrocortisone administration | — | — | — | — | — | 1 | |
| Expanded antimicrobial therapy | — | — | — | — | — | 1 | |
| Tamoxifen, Letrozole, Anastrozole, or Exemestane | — | — | — | — | — | 1 | |
| Pralatrexate | — | — | — | — | 3 | ||
| Pembrolizumab | — | — | — | — | 2 | ||
| Romidepsin | — | — | — | — | — | 2 | |
| Alanyl-glutamine | — | — | — | — | 4 | ||
| Doxorubicin | — | — | — | — | — | 2 | |
| Vinblastine | — | — | — | — | — | 1 | |
| Dacarbazine | — | — | — | — | — | 1 | |
| Brentuximab vedotin | — | — | — | — | — | 1 | |
| EGFR FPBMC | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| 5-Azacitidine | — | — | — | — | — | 1 | |
| Cardioprotection | — | — | — | — | — | 1 | |
| Azacytidine | — | — | — | — | — | 1 | |
| Belinostat | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Anoro Ellipta | — | — | — | — | — | 1 | |
| Arnuity Ellipta | — | — | — | — | — | 1 | |
| HER2 FPBMC | — | — | — | — | — | 1 | |
| GLP-1 receptor agonist | — | — | — | — | — | 1 | |
| Semaglutide Pen Injector | — | — | — | — | — | 1 | |
| Hyperpolarized Xenon129 | — | — | — | — | — | 1 |
53 more active programs hidden
Next readouts
- 2020-06-30
- 2022-12
- 2023-02
- 2023-07-15
- 2023-12-31
- 2023-12-31
- 2023-12-31
- 2024-11-30
- 2025-01-31
- 2025-07-24
Top conditions
- Type 1 Diabetes Mellitus27
- Polycystic Ovary Syndrome23
- Diabetes Mellitus, Type 122
- Type 1 Diabetes15
- Obesity14
- Breast Cancer13
- Hyperandrogenism10
- Hyperandrogenemia9
Frequently asked questions about University of Virginia
- How many clinical trials does University of Virginia have on ClinicalTrials.gov?
- University of Virginia is listed as the lead sponsor on 662 clinical trials in ClinicalTrials.gov, 138 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Virginia's trials are in Phase 3?
- 34 of University of Virginia's trials are in Phase 3, spread across 93 active drug programs.
- What therapeutic areas does University of Virginia focus on?
- University of Virginia's most-studied conditions on ClinicalTrials.gov are Type 1 Diabetes Mellitus, Polycystic Ovary Syndrome, Diabetes Mellitus, Type 1, Type 1 Diabetes, Obesity.
- When are University of Virginia's next clinical trial readouts?
- University of Virginia has 10 upcoming primary-completion readouts tracked here; the soonest is “Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy”, expected around 2020-06-30.